PRL and neoplasm: In prolactinomas, medical therapy relies on the preferential use of CAB compared to BRC because of the higher affinity of CAB to D2DR than BRC, its better tolerability profile, and its higher and long-lasting efficacy in normalizing prolactin (PRL) levels and in inducing tumor shrinkage (6).